10 results about "Cell-Free Nucleic Acids" patented technology

The present disclosure provides a probabilistic model for accurate and sensitive somatic single nucleotide variant (SNV) detection in cell-free nucleic acid samples comprising a set of sequence data. A joint genotype may be determined for each locus in the set of sequence data, and germline mutations may be intrinsically removed. A set of filtrations can be applied to eliminate low quality somatic variant calls. Further, a global tumor cell-free deoxyribonucleic acid (cfDNA) fraction and overlapping read mates can be considered, thereby enabling accurate SNV detection and variant allele frequency estimation from samples with low tumor cfDNA fraction. A sensitive early detection of minimal residual disease (MRD) is designed by using the probabilistic model and the machine learning model for distinguishing true variants from sequencing errors.

Disclosed herein are methods, compositions, and devices for diagnosing and treating cancer. The methods include sequencing a set of regions in cell-free nucleic acid molecules and detecting one or more biomarkers indicative of cancer and cancer subtype typing ability.

Provided herein are improved methods and systems for sequencing cell-free nucleic acids (cfNA) in a sample to generate sequencing reads. In some cases, the sample contains target cfNA from a pathogen and contaminant nucleic acids from a sample collection site. The methods and systems described herein can distinguish the sequencing reads originated from the target cfNA from contaminants nucleic acids and thereby accurately identify the target cfNA in the sample.

The present invention provides methods for using drain fluid obtained from medical procedures to assess diagnostic biomarkers indicative of disease obtained from drain fluid. In some embodiments, the diagnostics biomarkers are cell-free nucleic acids. In some embodiments, the disease is cancer. In some embodiments, a library of cfDNA is prepared and / or sequenced. In some embodiments, the methods comprise extracting nucleic acid from surgical drain fluid; conducting a size selection procedure to isolate cell-free nucleic acid from the surgical drain fluid; and detecting the cell-free nucleic acid.

Processes and materials to detect neoplasms from a biopsy are described. Processes and materials to build a sequencing library are described. Processes and material to perform targeted sequencing are described. Processes and materials to mitigate confounding sources are described. Cell-free nucleic acids can be sequenced and the sequencing result can be utilized to detect sequences derived from a neoplasm.

The present invention relates to a method for diagnosing cancer and predicting cancer type using cell-free nucleic acid fragment end motif frequency and size, and more specifically, to a method for diagnosing cancer and predicting cancer type in which a nucleic acid is extracted from a biological sample, the end motif frequency of a nucleic acid fragment and the size of the nucleic acid fragment are derived on the basis of reads aligned by obtaining sequence information, and then a value calculated by generating the derived end motif frequency and size as vectorized data and post-processing same and then inputting the post-processed vectorized data to a learned artificial intelligence model is analyzed. A method for diagnosing cancer and predicting cancer type using the end motif frequency and size of a cell-free nucleic acid fragment according to the present invention generates vectorized data and analyzes same using an AI algorithm, and thus exhibits high sensitivity and accuracy even if read coverage is low. Therefore, the method is useful.

Methods, compositions, and devices for use in the early detection of cancer are disclosed herein. A method comprises the steps of sequencing a panel of regions within cell-free nucleic acid molecules and detecting one or more biomarkers that indicate cancer. A method is described herein that comprises the steps of determining the state of biomolecules obtained from a sample derived from a human subject, testing for minimal residual disease (MRD), determining the likelihood of recurrence based on the MRD test, and scheduling one or more additional MRD tests based on the determination of the likelihood of recurrence.

Disclosed herein are methods of processing a sample comprising cell-free NA which can comprise microbial cell-free NA. Microbial cell-free NA can be differentiated from host NA via analysis of oxidative stress markers. Analysis of oxidative stress markers comprised in microbial cell-free NA can be utilized to characterize an infection and / or determine a diagnosis and / or a course of treatment for an infection.